SCYNEXIS wins BARDA contract worth up to $214 million for SCY-247 development
Bitget2026/09/28 11:31- SCYNEXIS won a BARDA contract worth up to USD 214 million to fund development of its SCY-247 antifungal through potential NDA submissions.
- Base period provides USD 18.5 million to move oral and IV SCY-247 into a Phase 2 trial for invasive candidiasis.
- Contract includes an option to support a second indication focused on prevention in high-risk patients; term can extend up to 10 years.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Synopsys (SNPS.US) partners with OpenAI to develop AI models for chip design, revenue-sharing model drives stock price up by 7%
On Wednesday, chip design software provider Synopsys (SNPS.US) announced that it has reached a partnership agreement with OpenAI. Both parties will jointly develop AI models for the chip business and share related revenues.
BoJ Summary of Opinions: Member says appropriate to keep raising rates in line with economy, price
Rio Tinto secures Bell Bay aluminum smelter operations till 2031
The British Pound rallies on a UK growth upgrade and gives more than half back
Crypto prices
More
